French imaging software developer Median Technologies said it has been chosen to provide imaging products and services for interpretation and management of medical images in oncology clinical trials, cancer screening programs, and routine practice in oncology.
The three projects, totaling 2.67 million euros, include:
- A phase II non-small cell lung cancer study valued at 1.08 million euros
- A phase II colorectal cancer study worth 1.44 million euros
- A phase II pancreatic adenocarcinoma trial totaling 248,000 euros.
The three studies are sponsored by two biotechnology firms specializing in oncology and immuno-oncology, Median said.
